Big pharmaceutical companies are boosting their production capacity of branded pharmaceutical products with billions of dollars in new U.S. manufacturing plant construction, but generic drug production still remains mostly overseas. The FDA is addressing this imbalance through a new pilot program that incentivizes domestic manufacturing of generic drugs by speeding up the regulatory review of these medicines.

Under the new pilot program announced Friday, eligible drugmakers must source the ingredients and make the finished drug product within U.S. borders. These requirements are consistent with other initiatives the Trump administration has introduced as part of a broader strategy to reshore pharmaceutical manufacturing.

More than half of pharmaceuticals distributed in the U.S. are man

See Full Page